CapsoVision
CapsoVision's revenue rose 15.3% to $14 million in fiscal 2025. Its operating margin was −188.2%, down from −169.4% a year earlier. Free cash flow was −$23 million. The diluted share count rose 1115.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
What CapsoVision does
CapsoVision makes capsule endoscopy products, which are swallowable capsules with cameras that take pictures of the digestive tract so that doctors can look for abnormalities. The company is based in Saratoga, California, and was incorporated in 2005.
Its product is the single-use CapsoCam capsule, which has a panoramic view and stores its video on board. Doctors can stream the video from the cloud with CapsoCloud software, or download it from the capsule and review it with CapsoView software. Its current small-bowel capsule, CapsoCam Plus, was cleared by the FDA in 2016 and has been sold in the U.S. since 2017 and in Europe since 2012.
CapsoCam Plus brought in about $13.6 million of revenue in 2025. The company has submitted an update to the FDA that adds AI-assisted detection of abnormalities, and it is working on a capsule for the colon, called CapsoCam Colon. Its audited financial statements say there is substantial doubt it can keep operating as a going concern.
Its biggest risks, as it describes them
- Its auditors' statements raise substantial doubt about its ability to continue as a going concern.
- It depends on growing sales of one product, CapsoCam Plus, and may be unable to expand to the colon or beyond.
- A failure or defect in a capsule could harm its reputation and lead to liability.
- Trade, tariff and geopolitical risks, and the risks of expanding into new countries.
Income statement
CapsoVision lost money in fiscal 2025: a net loss of $25 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | — | — |
| Debt incl. finance leases | — | — |
| Net debt (negative means net cash) | — | — |
| Net debt to EBITDA | — | — |
| Debt to equity | — | — |
| Interest coverage | — | −1,701.1x |
| Current ratio | 8.2x | 3.8x |
| Quick ratio | 6.8x | 3.1x |
Cash flow
Projections
Project CapsoVision's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $16.0 million of CapsoVision shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | Eliyahou Et Al Harari10% owner | Bought | 1,757,469 | $5.69 | $10.0 million | Form 4 |
| Sep 15, 2026 | Ching Hang Shen10% owner | Bought | 878,734 | $5.69 | $5.0 million | Form 4 |
| Jul 17, 2026 | Eliyahou Et Al Harari10% owner | Bought | 61,068 | $6.73 | $410,988 | Form 4 |
| Jul 8, 2026 | Eliyahou Et Al Harari10% owner | Bought | 81,300 | $6.09 | $495,117 | Form 4 |
| Jun 26, 2026 | Eliyahou Et Al Harari10% owner | Bought | 13,850 | $7.35 | $101,798 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY25 |
|---|---|
| Piotroski F-score | — |
| Rule of 40 | −154.1% |
| Altman Z'' | −30.12 |
| Accruals ratio | −14.0% |
The nine F-score tests
| Test | FY25 |
|---|---|
| Net income is positive | Fail |
| Cash from operations is positive | Fail |
| Return on assets rose | — |
| Cash from operations exceeds net income | Pass |
| Debt fell relative to assets | — |
| Current ratio rose | Fail |
| Share count didn't rise | Fail |
| Gross margin rose | Fail |
| Revenue rose relative to assets | — |
| F-score | — |
Compare
Put CapsoVision side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| CapsoVision | FY25 | 15.3% | −188.2% | −169.3% | — | — | — | |
| Hyperfine | FY25 | 5.2% | −273.4% | −214.8% | — | — | — | Compare |
| Nano-X Imaging | FY25 | 15.4% | −600.8% | −345.6% | — | — | — | Compare |
| Elutia | FY25 | −15.0% | −218.9% | −379.8% | — | — | — | Compare |
| Profound Medical | FY25 | 50.7% | −256.3% | −238.4% | −304.9% | — | 5 | Compare |
2 years of figures
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Revenue | 12 | 14 |
| Revenue growth | — | 15.3% |
| Gross profit | 6 | 7 |
| Research and development | 15 | 18 |
| Operating income | −20 | −26 |
| Net income | −20 | −25 |
| Diluted EPS (US$) | −9.85 | −1.03 |
| Diluted shares (millions) | 2 | 25 |
| Cash flow | ||
| Cash from operations | −20 | −23 |
| Capital expenditure | 0 | 0 |
| Free cash flow | −20 | −23 |
| Dividends paid | 0 | 0 |
| Share buybacks | 0 | 0 |
| Acquisitions | 0 | 0 |
| Stock-based compensation | 0 | 1 |
| Balance sheet at fiscal year end | ||
| Cash and short-term investments | — | — |
| Debt incl. finance leases | — | — |
| Total assets | 17 | 18 |
| Total liabilities | 3 | 5 |
| Shareholders' equity | −130 | 13 |
| Margins and ratios | ||
| Gross margin | 54.2% | 52.9% |
| Operating margin | −169.4% | −188.2% |
| Net margin | −169.3% | −186.8% |
| Free cash flow margin | −172.2% | −169.3% |
| Rule of 40 (growth + FCF margin) | — | −154.1% |
| Return on capital | — | — |
| Return on equity | — | — |
| Return on assets | — | −144.8% |
| Net debt to EBITDA | — | — |